Clinical guideline update reports confirmed visual field defects in children treated with vigabatrin, highlighting the necessity of revised safety standards.
EDITOR—In 1998 a paediatric advisory group in the United Kingdom produced a guideline to help clinicians when prescribing vigabatrin in children.1 The visual field defect reported in association with the drug 2 has now been confirmed in five children treated with it. The paediatric guideline has now been revised and replaced with the one below, which reflects the current opinion of the advisory group.
No takes yet. Share an insight, caveat, or question.
Vigabatrin Paediatric Advisory Group (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: